M. Shapiro
Physics and Astronomy · University of Michigan
Established · publishing since 1968Rising activity
Particle physics theoretical and experimental studiesHigh-Energy Particle Collisions ResearchQuantum Chromodynamics and Particle InteractionsParticle Detector Development and PerformanceDark Matter and Cosmic Phenomena
Publications
2,315
Citations
135,285
Est. group size
~6
Recurring co-author estimate
Active years
59
Publishing since 1968
In context
Among 1,217 established Physics and Astronomy PIs within our index
Citations: 135,285p25 1,394 · p75 14,296 · cohort median 4,808
Publications / year (recent): 94.6p25 2 · p75 16.8 · cohort median 5.4
Typically publishes in teams of ~14 · 13% small-team papers (≤3 authors) · across 3 venues
Publication cadence
Publications per year over the last 10 years — averaging 94.6/year recently
Recent publications
- W+D Charm Jet Fragmentation
2024
- Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies
Preprints.org · 2023
- Data from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
2023
- Supplementary Table S2. ALFA-0701 - Adverse Events in Consolidation 1 from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
2023
- Supplementary Table S1. ALFA-0701 - Adverse Events in Induction from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
2023
- Supplementary Table S1. ALFA-0701 - Adverse Events in Induction from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
2023
- Supplementary Table S5. Individual Patient Data Meta-Analysis - Randomized Trials from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
2023
- Supplementary Table S4. ALFA-0701 Search Strategy for Grouped Terms, MedDRA v18.0 from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
2023
- Supplementary Table S2. ALFA-0701 - Adverse Events in Consolidation 1 from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
2023
- Supplementary Table S4. ALFA-0701 Search Strategy for Grouped Terms, MedDRA v18.0 from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
2023
- Supplementary Table S3. ALFA-0701 - Adverse Events in Consolidation 2 from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
2023
- Supplementary Table S3. ALFA-0701 - Adverse Events in Consolidation 2 from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
2023
- Supplementary Table S5. Individual Patient Data Meta-Analysis - Randomized Trials from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
2023
- Data from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
2023
- The Survey of Transiting Extrasolar Planets at the University of Pittsburgh
American Astronomical Society Meeting Abstracts #235 · 2020
Publishes in
- Journal of High Energy Physics×289
- The European Physical Journal C×247
- Physics Letters B×124
- Physical review. D/Physical review. D.×113
- arXiv (Cornell University)×84
Similar researchers
By research-topic overlap
- A. Frankenthal
Physics and Astronomy · Purdue University West Lafayette
- A. Boveia
Physics and Astronomy · The Ohio State University
- A. Belyaev
Physics and Astronomy · The Ohio State University
- A. Babaev
Physics and Astronomy · The Ohio State University
- A. K. Virdi
Physics and Astronomy · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile